Aerobic, Strength, Kegel (ASK) Exercise Intervention Perceptions for Postpartum Health (ASK)
tiistai 1. syyskuuta 2026 päivittänyt: LAI KWAN LAM, Chinese University of Hong Kong
Aerobic, Strength, Kegel (ASK) Exercise Intervention Perceptions for Postpartum Health: a Pilot Randomized Controlled Trial
The goal of this pilot clinical trial is to learn whether a 12-week home-based exercise programme is feasible, acceptable, and safe for postpartum women in Hong Kong who had hypertensive disorders of pregnancy. The exercise programme is called the Aerobic, Strength, and Kegel exercise programme, or ASK programme.
The main questions this study aims to answer are:
- Can postpartum women follow the ASK exercise programme at home?
- Is the ASK exercise programme acceptable and safe?
- Does the ASK exercise programme show early benefits for postpartum recovery and health?
Researchers will compare women who receive the ASK exercise programme with women who receive standard postnatal care.
Participants will be randomly assigned to one of the two groups. They will complete study assessments at the beginning of the study and after 12 weeks. Women in the ASK exercise programme group will complete three 60-minute exercise sessions per week for 12 weeks, supported by a mobile app and wearable device. Women in the standard postnatal care group will continue to receive usual postnatal care.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
This is a parallel-group pilot randomized controlled trial designed to evaluate the feasibility, acceptability, safety, and preliminary effectiveness of the ASK Programme, a 12-week home-based postpartum exercise intervention for Asian women in Hong Kong. The ASK Programme combines aerobic training, strength training, and Kegel-based pelvic floor muscle training, and is delivered through a study app with wearable-supported monitoring.
Eligible participants will be enrolled at 6 to 8 weeks postpartum and randomized in a 1:1 ratio to either the ASK Programme intervention group or the standard postnatal care control group. Participants in the intervention group will complete three home-based ASK exercise sessions per week for 12 weeks. Each session will include warm-up, aerobic training, strength training, pelvic floor muscle training, and cool-down. The control group will receive standard postnatal care.
Assessments will be conducted at baseline and within 1 week after completion of the 12-week intervention. The study will collect feasibility, adherence, safety, acceptability, clinical, behavioral, psychosocial, physiological, cardiometabolic, and exploratory biological data to inform the design of a future full-scale randomized controlled trial.
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
40
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: LAI KWAN LAM, PhD
- Puhelinnumero: +85235054267
- Sähköposti: laikwanlam@cuhk.edu.hk
Opiskelupaikat
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong
- The Department of Obstetrics and Gynaecology, The Chinese University Of Hong Kong
-
Ottaa yhteyttä:
- YAO WANG, PhD
- Puhelinnumero: +85235051289
- Sähköposti: yaowang1@cuhk.edu.hk
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Inclusion Criteria:
- Female Asian postpartum women aged 18 to 45 years
- Singleton pregnancy
- 6 to 8 weeks postpartum at the time of enrolment
- Medically stable after childbirth
- Physically able to participate in low-to-moderate intensity exercise training
- Able and willing to participate in the 12-week study programme
- Able to use the study app and wearable device, or willing to receive instruction on their use
- Able to provide written informed consent
Exclusion Criteria:
- Multiple pregnancy
- Severe postpartum medical complications or conditions contraindicating exercise participation
- Severe cardiovascular, respiratory, neurological, or major musculoskeletal conditions that may limit safe participation in exercise
- Current use of medication likely to substantially affect cardiac function, including heart failure therapy
- Antibiotic treatment within the preceding month
- Severe mental illness or other condition affecting the ability to provide informed consent or comply with study procedures
- Any medical, obstetric, or psychological condition judged by the research team or attending clinician to make participation unsafe or inappropriate
- Inability or unwillingness to adhere to the 12-week ASK programme or study assessments
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: ASK Exercise Programme
Participants assigned to this arm will receive the Aerobic, Strength, and Kegel exercise programme (ASK programme) in addition to standard postnatal care.
The ASK programme is a 12-week home-based, app-guided exercise intervention supported by a wearable device.
Participants will be asked to complete three exercise sessions per week, with each session lasting approximately 60 minutes.
The programme includes aerobic exercise, strength training, and Kegel-based pelvic floor muscle training.
|
The ASK Exercise Programme is a 12-week home-based, app-guided exercise intervention supported by a wearable device.
Participants will be asked to complete three sessions per week, with each session lasting approximately 60 minutes.
The programme includes aerobic exercise, strength training, and Kegel-based pelvic floor muscle training.
The mobile app and wearable device will be used to support exercise delivery, self-monitoring, and adherence tracking.
|
|
Ei väliintuloa: Standard Postnatal Care
Participants allocated to the control group will receive standard postnatal care, including routine postpartum follow-up and general health advice.
They will not receive the ASK programme during the 12-week study period.
They will complete the same baseline and post-intervention assessments as participants in the intervention group.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Recruitment rate to the ASK Exercise Programme
Aikaikkuna: From recruitment initiation to 12 weeks
|
Recruitment rate will be calculated as the number of participants enrolled divided by the number of eligible participants approached.
The outcome will be reported as a percentage of eligible participants approached.
|
From recruitment initiation to 12 weeks
|
|
Retention rate in the ASK Exercise Programme
Aikaikkuna: From baseline to 12 weeks
|
Retention rate will be calculated as the number of enrolled participants who complete the 12-week follow-up assessment divided by the total number of enrolled participants.
The outcome will be reported as a percentage of enrolled participants.
|
From baseline to 12 weeks
|
|
Dropout rate from the ASK Exercise Programme
Aikaikkuna: From baseline to 12 weeks
|
Dropout rate will be calculated as the number of participants who withdraw or are lost to follow-up before the 12-week assessment divided by the total number of enrolled participants.
The outcome will be reported as a percentage of enrolled participants.
|
From baseline to 12 weeks
|
|
Assessment completion in the ASK Exercise Programme
Aikaikkuna: From baseline to 12 weeks
|
Assessment completion rate will be calculated as the number of completed planned study assessments divided by the total number of planned study assessments.
The outcome will be reported as a percentage of planned study assessments.
|
From baseline to 12 weeks
|
|
Participant satisfaction rate
Aikaikkuna: At 12 weeks
|
Participant satisfaction will be assessed using a study-specific acceptability questionnaire administered at 12 weeks.
Satisfaction will be defined as reporting "satisfied" or "very satisfied" with the ASK Exercise Programme.
The outcome will be reported as the percentage of participants who are satisfied or very satisfied.
|
At 12 weeks
|
|
ASK session completion rate
Aikaikkuna: Throughout the 12-week intervention period
|
ASK session completion rate will be calculated as the number of prescribed ASK exercise sessions completed divided by the total number of prescribed ASK exercise sessions during the 12-week intervention period.
Session completion will be assessed using app-recorded exercise completion data.
The outcome will be reported as a percentage of prescribed ASK exercise sessions.
|
Throughout the 12-week intervention period
|
|
Adverse events related to the ASK Exercise Programme
Aikaikkuna: Throughout the 12-week intervention period
|
Safety will be assessed as the number of participants who experience one or more adverse events related to the ASK Exercise Programme during the 12-week intervention period.
Adverse events and exercise-related symptoms will be collected using participant symptom reports and study adverse event records.
The outcome will be reported as the number of participants with adverse events related to the ASK Exercise Programme.
|
Throughout the 12-week intervention period
|
|
Postpartum recovery score
Aikaikkuna: Baseline and 12 weeks
|
Postpartum recovery will be assessed using the Obstetric Quality of Recovery-10.
The change from baseline to 12 weeks in the total Obstetric Quality of Recovery-10 score will be calculated.
Total scores range from 0 to 100, with higher scores indicating better postpartum recovery.
|
Baseline and 12 weeks
|
|
Postnatal depressive symptom score
Aikaikkuna: Baseline and 12 weeks
|
Postnatal depressive symptoms will be assessed using the Edinburgh Postnatal Depression Scale.
The change from baseline to 12 weeks in the total Edinburgh Postnatal Depression Scale score will be calculated.
Total scores range from 0 to 30, with higher scores indicating more severe depressive symptoms.
|
Baseline and 12 weeks
|
|
Pelvic floor symptom distress score
Aikaikkuna: Baseline and 12 weeks
|
Pelvic floor symptom distress will be assessed using the Pelvic Floor Distress Inventory-20.
The change from baseline to 12 weeks in the total Pelvic Floor Distress Inventory-20 score will be calculated.
Total scores range from 0 to 300, with higher scores indicating greater pelvic floor symptom distress.
|
Baseline and 12 weeks
|
|
Sleep quality score
Aikaikkuna: Baseline and 12 weeks
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index.
The change from baseline to 12 weeks in the global Pittsburgh Sleep Quality Index score will be calculated.
Global scores range from 0 to 21, with higher scores indicating poorer sleep quality.
|
Baseline and 12 weeks
|
|
Breastfeeding self-efficacy score
Aikaikkuna: Baseline and 12 weeks
|
Breastfeeding self-efficacy will be assessed using the Breastfeeding Self-Efficacy Scale-Short Form.
The change from baseline to 12 weeks in the total Breastfeeding Self-Efficacy Scale-Short Form score will be calculated.
Total scores range from 14 to 70, with higher scores indicating greater breastfeeding self-efficacy.
|
Baseline and 12 weeks
|
|
Health-related quality of life score
Aikaikkuna: Baseline and 12 weeks
|
Health-related quality of life will be assessed using the Short Form-12 Health Survey.
The change from baseline to 12 weeks in the health-related quality of life score will be calculated.
The outcome will be reported as a score on a scale, with higher scores indicating better health-related quality of life.
|
Baseline and 12 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Body mass index
Aikaikkuna: Baseline and 12 weeks
|
Body mass index will be calculated as body weight in kilograms divided by height in meters squared.
The change from baseline to 12 weeks in body mass index will be calculated.
The outcome will be reported in kg/m².
|
Baseline and 12 weeks
|
|
Waist-hip ratio
Aikaikkuna: Baseline and 12 weeks
|
Waist-hip ratio will be calculated as waist circumference divided by hip circumference.
The change from baseline to 12 weeks in waist-hip ratio will be calculated.
The outcome will be reported as a ratio.
|
Baseline and 12 weeks
|
|
Resting heart rate
Aikaikkuna: Baseline and 12 weeks
|
Resting heart rate will be measured at baseline and 12 weeks.
The change from baseline to 12 weeks in resting heart rate will be calculated.
The outcome will be reported in beats per minute.
|
Baseline and 12 weeks
|
|
Systolic blood pressure
Aikaikkuna: Baseline and 12 weeks
|
Systolic blood pressure will be measured at baseline and 12 weeks where available through home or routine clinical measurement.
The change from baseline to 12 weeks in systolic blood pressure will be calculated.
The outcome will be reported in mmHg.
|
Baseline and 12 weeks
|
|
Diastolic blood pressure
Aikaikkuna: Baseline and 12 weeks
|
Diastolic blood pressure will be measured at baseline and 12 weeks where available through home or routine clinical measurement.
The change from baseline to 12 weeks in diastolic blood pressure will be calculated.
The outcome will be reported in mmHg.
|
Baseline and 12 weeks
|
|
Fasting glucose concentration
Aikaikkuna: Baseline and 12 weeks
|
Fasting glucose concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in fasting glucose concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
HbA1c
Aikaikkuna: Baseline and 12 weeks
|
HbA1c will be measured using blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in HbA1c will be calculated.
The outcome will be reported as a percentage.
|
Baseline and 12 weeks
|
|
Triglyceride concentration
Aikaikkuna: Baseline and 12 weeks
|
Triglyceride concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in triglyceride concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
Total cholesterol concentration
Aikaikkuna: Baseline and 12 weeks
|
Total cholesterol concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in total cholesterol concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
High-density lipoprotein cholesterol concentration
Aikaikkuna: Baseline and 12 weeks
|
High-density lipoprotein cholesterol concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in high-density lipoprotein cholesterol concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
Low-density lipoprotein cholesterol concentration
Aikaikkuna: Baseline and 12 weeks
|
Low-density lipoprotein cholesterol concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in low-density lipoprotein cholesterol concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
Post-exercise recovery heart rate
Aikaikkuna: Baseline and 12 weeks
|
Cardiorespiratory fitness will be assessed using a 3-minute step test.
Post-exercise recovery heart rate will be recorded after completion of the test.
The change from baseline to 12 weeks in post-exercise recovery heart rate will be calculated.
The outcome will be reported in beats per minute.
|
Baseline and 12 weeks
|
|
Daily step count
Aikaikkuna: Throughout the 12-week intervention period
|
Daily step count will be recorded using wearable-derived activity data.
Mean daily step count during the 12-week intervention period will be calculated.
The outcome will be reported as steps per day.
|
Throughout the 12-week intervention period
|
|
Daily active minutes
Aikaikkuna: Throughout the 12-week intervention period
|
Daily active minutes will be recorded using wearable-derived activity data.
Mean daily active minutes during the 12-week intervention period will be calculated.
The outcome will be reported as minutes per day.
|
Throughout the 12-week intervention period
|
|
Exploratory gut microbiome profile
Aikaikkuna: Baseline and 12 weeks
|
Gut microbiome profiles will be assessed using stool samples collected at baseline and 12 weeks.
Changes from baseline to 12 weeks in gut microbiome profiles will be explored, including microbial diversity and taxonomic composition, depending on sample availability and sequencing quality.
|
Baseline and 12 weeks
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Tutkijat
- Päätutkija: Yao Wang, PhD, Chinese University of Hong Kong
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Tiistai 1. joulukuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Perjantai 30. marraskuuta 2029
Opintojen valmistuminen (Arvioitu)
Perjantai 30. marraskuuta 2029
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Tiistai 28. heinäkuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Maanantai 24. elokuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Torstai 27. elokuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Torstai 3. syyskuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 1. syyskuuta 2026
Viimeksi vahvistettu
Keskiviikko 1. heinäkuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- CREC Ref. No.:2026.436
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .